Stephen Strittmatter on a first-in-human trial for treating chronic cervical spinal cord injury

Stephen Strittmatter (Yale School of Medicine, CT, USA) discusses his first-in-human and randomised trial of a soluble Nogo-receptor-Fc decoy in patients with chronic cervical spinal cord injury. The Article is published in the August issue of The Lancet Neurology. Read the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00215-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_laneur Continue this conversation on social! Follow us today at... https://thelancet.b...

Om Podcasten

Editors at The Lancet Neurology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.A monthly audio companion to the journal, this podcast covers a broad range of topics, from sleep habits to amyloid biomarkers in Alzheimer’s, the diagnosis and classification of optic neuritis to treatment of Creutzfeldt-Jakob disease, and more.